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ABSTRACT 
Brain derived neurotrophic factor is a neurotrophin of vital importance for 
neuron survival. 
It may therefore be of great help to people affected by sensorineural 
hearing loss and cochlear implant users, as it has already been 
demonstrated that it maintains neuronal cells alive and this proved to be 
necessary for the device to work. 
The issue with its clinical application is related to its large size that makes 
it difficult to deliver. 
In this thesis I took on one of the tasks of a European project.  
The objective of the Nanoear project is the creation of multifunctional 
nanoparticles that could be used as drug carriers for a target delivery in the 
inner ear. 
The final aim is to find a substitute for BDNF protein, able to mimic its 
action but small enough to be attached to the nanoparticles and carry them 
to their target in the inner ear. 
The best method to obtain small peptides with these features is the phage 
display. This technique allows selection of a pool of specific peptides 
binding specifically to an immobilized target. 
In collaboration with an English company involved in the project as well, 
we worked to set all the parameters in order to make the phage display for 
this project feasible. 
As our goal was attaining BDNF mimetic peptides our target had to be its 
functional receptor, TrkB. 
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Starting from a polyA+ RNA library from adult human brain we could get 
the genes coding for TrkB and BDNF and follow all the process up to the 
expression of the two proteins in bacteria and in eukaryotic cells, as well. 
In order to include into nanoparticles the most specific peptides many 
approaches for the phage display were taken into consideration and 
experimented on. 
This technique was in fact performed in vivo on guinea pigs and all the 
parameters were set for different trials in vitro either on eukaryotic cells or 
on the specific binding domain purified from bacteria. 
Therefore the results and the data obtained in this study can lead to a new 
generation of drug with great clinical potential.  
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1 INTRODUCTION 
 
Hearing impairment is a full or partial decrease in the ability to detect or 
understand sounds which can be caused by a wide range of factors. 
It has a huge impact on the population as it affects more than 560 million 
people worldwide (80 million just in Europe) and about one sixth of the 
population of Italy. 
According to the World Health Organization it is very likely that by 2050, 
hearing loss will rise to 900 million worldwide. 
The incapability of hearing has disastrous effects on people’s social and 
working life because it eventually leads to the isolation of the individual by 
limiting his skill to communicate with the rest of the world.  
Those born with a severe hearing loss have very limited chance of learning 
to speak and develop oral language because of the complete absence of 
sound input and this could eventually lead to poorer educational outcomes. 
As for the adults who develop a severe hearing loss, losing vocational skills 
and social interaction proves to be traumatic.  
Furthermore, individuals with a severe to profound hearing loss often 
exhibit signs of paranoia and depression (Maillet et al, 1995).  
Subjects with hearing impairment are likely to be more vulnerable to 
depression but also physical and mental illnesses (Van Oyen et al, 2001). 
Moreover hearing impairment will represent an increasing challenge to 
public health as lifespan increases and the general population ages. 
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There are different types of hearing loss according to the part that is 
actually damaged. 
The ear consists of three parts: the outer ear, the middle ear and the inner 
ear.  
 
Figure 1.1 scheme of the ear (image from www.utdol.com) 
Based on the area affected we can then refer to conductive or sensorineural 
hearing loss. 
Conductive hearing loss is caused by a mechanical problem in the ear canal 
or the middle ear that blocks the conduction of sound. It can be easily 
corrected with hearing aids.  
Sensorineural hearing loss is caused by damage to the inner ear, auditory 
nerve or auditory nerve pathways in the brain. 
Cochlear hearing loss occurs when the structures inside the cochlea are 
damaged. This can occur in several different ways, such as exposure to 
ototoxic chemicals or intense sounds, infection, metabolic disfunctions, 
allergies, or as a result of genetic factors (Waters C, 1999). 
The damage may extend beyond the cochlea to include higher centres in 
the auditory pathway. The more general term of sensorineural hearing loss 
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is used to describe a hearing loss where damage occurs to either the cochlea 
or neural structures. 
About the 90% of the people with hearing impairments present damage to 
the cochlear structures and one out of a thousand children is affected by a 
congenital sensorineural deafness. 
In contrast with other species which can produce or regenerate cells (Stone 
et al, 2007) involved in hearing throughout their life, mammalians hair cell 
when deteriorated are lost thus creating an irreversible situation. 
 
1.1 The cochlear implant 
While patients with a partial hearing loss could be helped with hearing aids, 
which just amplify the loudness of sounds, in cases where the auditory 
system is more profoundly damaged and the functionality of the organ is 
compromised  the only possible treatment is the cochlear implant: 
regardless of how amplified the sounds are they will not be perceived. 
Usually in patients with a severe hearing loss a portion of the auditory 
nerve cells is still  functional, and cochlear implants are meant to 
electrically stimulate those neuronal cells, thus bypassing the damaged 
parts of the auditory system. 
In cochlear implants, also called bionic ear, the damaged structures are 
replaced with a wire that is implanted in the cochlea. 
The hearing process is stimulated when sound waves are perceived by a 
microphone that hangs over the back of the ear, then sounds are passed via 
a thin wire to a speech processor that amplifies and filters sounds before 
converting it into digital signals. 
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These are sent back via the same wire to a transmitter which in turn sends 
radio signals to a receiving unit embedded under the scalp. This stimulates 
the wire implanted in the cochlea enabling it to send clear signals to the 
auditory nerve. 
 
 
Figure 1.2 The cochlear implant (images taken from Cochlear and Medel 
websites) 
Although the surgery permanently damages the cochlea the implants can 
greatly improve hearing, even in people who are profoundly deaf and 
nowadays many patients can benefit from this system and hear again. 
Implant recipients have shown great improvements after getting the bionic 
ear, as many studies demonstrated (Oh et al., 2003). 
Moreover Blamey et al in 1996 could prove ongoing improvements in 
patients performances were related to the duration of implant use. 
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Therefore the use of cochlear implants really is a great benefit for deaf 
people as they can hear again, their tinnitus usually decreases and they can 
get their confidence back which helps improving on their conditions. 
Children implanted have especially shown great achievements in particular 
when it comes to learning to speak and so in their conversational fluency 
(Rubinstein, 2002; Tye-Murray, 2003) which helped them get better 
educational and vocational chances. 
The prosthesis however, has sometimes proven unsatisfactory because of 
the poor perception/discrimination of words or for aesthetic reasons.  
Many factors can determine great differences in individual outcomes, 
though, such as the age at onset of deafness, the age at implantation, the 
duration of this condition, the extent of residual hearing and the experience 
with the implant (Tong et al, 1988). 
This means that many improvements can still be done on the bionic ear in 
order to enhance its performance and allow deaf people to have better 
hearing capabilities (Wilson et al 2003). 
Several studies were brought on to enhance the efficacy of the cochlear 
implant either on the electronic device or on the possibility of using a 
combined pharmacological strategy to halt the ongoing and irreversible 
degeneration in the damaged auditory system. 
Indeed prosthesis function depends on survival and electrical excitability of 
the cochlear neurons (Nadol JB et al, 1989) but trauma and loss of cochlear 
inner hair cells causes a series of events that result first in the retraction of 
the peripheral processes of the auditory nerve, scar formation in the organ 
of Corti, and over the course of months to years the loss of auditory nerve 
cell bodies (spiral ganglion cells).  
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Degeneration of the auditory nerve occurs after lesions of its peripheral 
target field (organ of Corti), specifically, including loss of inner hair cells 
(IHCs).  
But a local treatment of the cochlea may enhance survival of auditory 
neurons. 
Several strategies have been taken into consideration in trying to ameliorate 
or prevent this pathological condition. 
The mechanism of cell death in the cochlea has been studied showing its 
two possible pathways: necrotic cell death mediated by very loud noise, or 
apoptosis, mediated by the activation of the caspases, a cysteine protease 
family within the cells.  
A pharmacological intervention on each of these two mechanisms: necrosis 
and apoptosis could provide the possibility to reduce and, in some cases, to 
prevent cochlear cell death. 
Among the prevention strategies considered the use of antioxidants, 
glutamate receptor antagonists, neurotrophins (Shinohara et al, 2002; 
Gillespie et al, 2004) and NOS inhibitors were evaluated (Fetoni, 2005). 
Many investigated the role of antioxidant agents in different models of 
peripheral hearing disorders and it resulted that antioxidants protect the 
cochlea from noise-induced trauma, as well as cisplatin and 
aminoglycoside exposure. 
Protection of auditory sensory cells from one of the major ototoxic drugs, 
that is cisplatin, is carried out at the molecular level by three mechanisms: 
prevention of ROS formation; neutralization of toxic products, and 
blockage of apoptotic pathways(Ciorba et al, 2008; Gabaizadeh et al 1997). 
Nowadays even cell regeneration through genic therapy appears as a 
feasible approach (Edge AS, 2008). 
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Cochlear hair cells and supporting cells derive from the same precursor 
cells during the embryogenesis but then differentiate thanks to many genes 
and factors. 
Recent experiments have given promising results concerning the processes 
related to inner ear damage. In the mammalian vestibular system, 
Kawamoto shown that hair cell regeneration can occur under certain 
circumstances (Kawamoto et al, 2009). 
In the auditory system there is evidence of hair cell regeneration in 
newborn mice given explants from cochlea and in replacing the damaged 
hair cells by converting the supporting cells using the gene Math 1 ( 
Kawamoto et al. 2003). 
Math 1 gene has been shown to act as a "pro-hair cell gene" and it has a 
crucial role in the differentiation of hair cells from multipotent progenitors.  
In 2005 Izumikawa et al. demonstrated that by using gene therapy the lost 
hair cells in mammals can regenerate and that hearing may be returned to 
the profoundly deaf mammalian ear.  
New hopes were raised after observing a spontaneous recovery of hearing 
after noise trauma in humans which implies that restoring the hearing 
function may be possible. 
Despite the fact that the mechanisms lying beneath the recovery have not 
yet been fully delineated, there is noteworthy evidence that cochlear 
damage induced by noise can be prevented by the application of different 
pharmacologically active substances.  
A feasible way of delivering drugs to the inner ear is under investigation 
because not all the approaches known are clinically and technically 
possible. 
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Drugs can reach the cochlea either locally, from the middle ear over the 
round window membrane (RWM) through permeation, or directly injected 
through the RWM or the oval window or with an osmotic pump (passing 
through the lateral wall of the cochlea) or by systemic application (orally, 
intravenously or via the cerebrospinal fluid) .  
A new approach that has been considered is the one involving the use of 
nanoparticles which can carry drugs and reach even the cells in the inner 
ear. 
I joined a European project whose goal is to develop novel multifunctional 
nanoparticles (MFNPs), which are targetable to selected cell populations, 
biodegradable, and with a high efficacy of transfection by biological 
surface modification. 
 
 
Figure 1.3 Nanoparticles comparison (from Nanoear website) 
One of the “challenges” of this project is the specific cell targeting of the 
nanoparticles.  
My particular aim is therefore to find targeting peptides mimicking the 
endogenous ligands, which can bind to specific receptors present on spiral 
ganglion cells, the TrkB receptors.  
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Peptides will be identified with the phage display screening. Such selection 
technique is also known as biopanning, and results in highly selective 
peptides binding to specified receptors, thus allowing accurate targeting. 
 
1.2 Anatomy of the inner ear 
The human auditory system comprises the ears and their connections to and 
within the central nervous system.  
The auditory system can be divided into the outer, middle, and inner ears, 
the auditory nerve, and the central auditory pathways.  
 
Figure 1.4 Anatomy of the inner ear (picture from Netter) 
The oval window separates the middle from the inner ear.  
This consists of sensory organs of hearing (the cochlea) and of balance (the 
semicircular canals, utricle, and saccule) whose name is vestibular system. 
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The cochlea forms a cone-shaped spiral with about 2 and ¾ turns. It is 
widest at the base and it narrows towards the apex.  
Figure 1.5 The cochlea (image taken from Gray) 
Two membranes, Reissner’s membrane and the basilar membrane, divide 
the cochlea along its length into three different chambers: scala media, 
scala vestibuli, and scala tympani.  
The Organ of Corti, which is located on the basilar membrane in the scala 
media consists of a single row of inner hair cells (IHCs), three to five rows 
of outer hair cells (OHCs), different types of supporting cells, and the pillar 
cells forming the tunnel of Corti which divides the OHCs from the IHCs.  
Most sensory hearing loss is due to poor hair cell function due to age, 
disease, damage or deformity of the cells. 
Either cochlear or vestibular sensory cells are called hair cells because they 
are characterised by having a cuticular plate on top with a variable number 
of stereocilia bathing in the surrounding endolymph.  
The cell body itself is instead located in the perilymph compartment.  
These two types of cells, inner hair cells and outer hair cells, differ by their 
position, shape and pattern of the stereocilia. 
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There are approximately 3500 IHCs and 12 000 OHCs in the cochlea 
(Simpson, 2007).  
IHCs are supported by phalangeal cells which hold their rounded base. 
The outer hair cells are longer and smaller and are supported by Dieter 
Cells.  Inner and outer hair cells differ from each other structurally, as well 
as functionally. The flask-shaped IHCs contain a huge system of 
tubulovessicular endoplasmic reticulum, Golgi apparatus and mitochondria 
(Lim, 1986). 
 
 
Figure 1.6 The organ of Corti (taken from ourworld.compuserve.com) 
This is probably a hint of a high level of metabolic activity, which may be 
related to the transduction of mechanical to electrochemical energy. 
Outer hair cells have a much more developed endoplasmic reticulum 
system and also contain contractile proteins as stereocilia and cuticular 
plates which enable them to actively contract and elongate (Slepecky et al, 
1988).  
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On top of the cuticular plate present at the surface of both inner and outer 
hair cells there are the stereocilia whose number varies based on the 
tonotopy. 
Each OHC contains as many as 150 stereocilia at the base and their number 
decrease to about 60 at the apex. Inner hair cells have circa 50-70 
stereocilia each that differ from the OCHs' for the fact they do not change 
in number and they are thicker.  
Another difference is that whereas OHC stereocilia are in contact with the 
overlying tectorial membrane, IHC stereocilia seem to have not to have 
contact with it.  
 
1.3 Perception of sound in the auditory system 
The tympanic membrane vibrates when it receives the sound waves 
travelling along the auditory canal.  
Its transmitted vibrations then pass through the middle ear and the three 
ossicles, the malleus, incus and stapes, to reach the oval window at the base 
of the cochlea.   
The vibrations delivered to the oval window cause the basilar membrane to 
move. 
This movement in turn stimulates a sideways motion of the tectorial 
membrane and of the stereocilia in contact with it. 
OCHs cilia bend because of a direct contact while the IHCs' will follow the 
fluid movement that comes with the tectorial membrane's vibration. 
When stereocilia bend transduction pores on their surface open allowing 
access to a channel through which ions can pass. 
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Immediately after in the space between the hair cell and the afferent nerve a 
neurotransmitter is released causing an excitatory response along the 
auditory nerve. 
This process transforms mechanical energy into electrical energy. 
The signal is then carried through the central auditory system to the 
auditory cortex in the brain. 
 
Figure 1.7 Schematic representation of the way acoustic signals are passed 
from the basilar membrane to the auditory nerve (taken from Simpson A, 
2007) 
Inner hair cells therefore are important as they translate mechanical 
movements in the cochlea into electrical stimuli and neural activity. They 
play a crucial role in conveying information about sound from the cochlea 
to higher auditory pathways via the afferent neurons.  
Outer hair cells instead influence the response of the basilar membrane 
changing their length, shape and stiffness in response to sound, so they are 
just a part of an “active mechanism” in the cochlea. 
Each hair cell has several contacts with neurons, finally ending in the spiral 
ganglion inside the modiolus.  
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Both types of hair cells are innervated by specific afferent and efferent 
systems forming a loop to and from the brainstem. 
 
Figure 1.8 Innervation of the hair cells (from Promenade 'round the 
cochlea website) 
The radial afferents (blue) and the lateral efferents (pink) innervate the 
inner hair cells; the spiral afferents (green) and the medial efferents (red) 
innervate the outer hair cells (Spoendlin, 1979, 1985 and 1988). 
IHCs are synaptically connected to all type I spiral ganglion neurons 
forming the radial afferent system (blue) going to the cochlear nuclei.  
The lateral efferent system (pink) coming from the small neurons in the 
ipsilateral lateral superior olivary complex creates a feedback control to the 
IHC/type I afferent synapse (Altschuler and Fex, 1996). 
 
Figure 1.9IHC innervation (from Promenade 'round the cochlea website) 
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On average, one IHC is innervated by ten synaptic complexes from afferent 
dendrites. 
These are made up of a radial afferent bouton (blue) and a lateral efferent 
ending (pink). 
 
 
Figure 1.10 OHC innervations (from Promenade 'round the cochlea 
website) 
The OHCs only synapse with a small number of small endings from type II 
spiral ganglion neurons, making up the spiral afferent system (green). 
Large neurons of the medial efferent system (red), from both sides of the 
medial superior olivary complex, form axo-somatic synapses with the OHC 
(Pujol, 1994). 
At the synaptic pole of the outer hair cells there are an afferent bouton 
(green) from a type II ganglion neuron and a medial efferent ending (red). 
The spiral ganglion derives from the primitive otocyst. It differentiates very 
early, before the organ of Corti (Torres and Giraldez, 1998) 
In man, it is composed of 30 to 35,000 bipolar neurons of two main types.  
Large and myelinated type I neurons (around the 95% of the total) are 
connected to inner hair cells; small and unmyelinated type II neurons are 
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connected to outer hair cells. Both types have central axons delivering 
signals to the cochlear nuclei. 
In mammals type I spiral ganglion neurons (95% of the ganglion neurons) 
have a single ending radially connected to IHCs (Berglund, Ryugo, 1987) 
Type II small, unmyelinated neurons penetrate the organ of Corti and spiral 
before branching to contact about ten OHCs, generally in the same row 
(Brown et al, 1988). 
 
Figure 1.11 Innervation of the cochlea (taken from Gillespie L, 2004) 
 
Cochlear implants can restore people's hearing bypassing the damaged 
areas of the auditory system but their efficacy depends totally upon SGN 
survival (Marzella and Clark, 1999) 
Response to electrical stimulation by neurons is highly affected by loss of 
dendrites, demyelination of axons and soma and shrinkage of neurons 
themselves (Leake and Hradek, 1988). 
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Patients could benefit from the cochlear prostheses just if the SGNs and the 
auditory nerve are alive and functional and the success of the device 
depends almost entirely upon the survival of these structures. 
Many studies on animals have shown that the ongoing degeneration of the 
neural cells close to the implant, could severely compromise the effects of 
the hearing device. 
Indeed Shepherd and Javel, 1997 and Hardie and Shepherd, 1999 revealed 
that in implanted animals ongoing SGN degeneration made perception of 
sound get worse. 
Despite this fact the same effect on humans carrying a cochlear implant has 
not yet been demonstrated. 
Ylikoski in the nineties remarked that SGNs could survive only if they 
maintain communication through synapses with their target and are 
supported by neurothrophins (generally expressed by hair cells). 
As the neuronal degeneration in the inner ear apart from being irreversible 
is also progressive in time, a way to improve the prosthesis performances 
could be preventing this process from starting. 
This could be achieved developing a pharmacological strategy able to halt 
or at least slow down neuronal degeneration in the inner ear, thus 
improving cochlear implants' performances too. 
Moreover, while conflicting results have been reported about the survival 
effects of chronic electrical stimulation on SGNs, it has been proven that 
BDNF delivery in conjunction with electrical stimulation of the nerve 
through a cochlear implant in deaf animals may result in enhanced SGN 
survival (Serruto et al, 2003). 
This could mean that allowing spiral ganglion neurons to live longer trying 
to promote their survival or blocking their degeneration may greatly 
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improve the hearing possibilities of cochlear implants recipients and thus 
have a great potential both clinically and commercially. 
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1.4 BDNF and the neurotrophic factors 
Neurotrophins are a family of homologous protein that tightly regulate the 
development and maintenance of the vertebrate neural system (Fritzsch et 
al, 1997) 
The neurotrophins, best known through the nerve growth factor (NGF) 
discovered by Levi-Montalcini in 1952, have six family members among 
vertebrates with a well-characterized molecular structure and an emerging 
evolutionary history. 
They are: the Nerve growth factor (NGF), brain-derived neurotrophic 
factor (BDNF), neurotrophin-3 (NT-3; also hippocampal-derived 
neurotrophic factor or HDNF), neurotrophin-4/5 (NT-4/5), neurotrophin-6 
(NT-6) and neurotrophin-7 (NT-7) (Lewin and Barde, 1996). 
They are small, basic homodimers consisting of two monomers, each of 
~120 residues, their dimeric form cause the receptor dimerization during 
the interaction. 
Neurotrophins share similar biochemical characteristics and are all 
synthesized as soluble precursor proteins, then modified by cleavage to 
mature forms, and secreted. 
Neurotrophins have a quite similar genetic pattern as they all have a single 
3’ coding exon and many upstream 5’ non coding exons separated by large 
introns (Liu et al, 2006).  
Different transcription processes result in the generation of many distinct 
neurotrophins transcripts which eventually evolve to identical protein 
(fig.1.12). 
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Figure 1.12 Schematic picture showing BDNF gene and protein (adapted 
from Rantamaki T, 2006) 
 
These trophic factors are synthesized as 30-35 kDa pro-NTs (Seidah et al., 
1996a; Seidah et al.1996b), which are then directed through the trans-Golgi 
apparatus to either constitutive (non-Ca2+-dependent) or regulatory (Ca2+-
dependent) secretory vesicles (Lessmann et al,2003).  
Pro-NTs are cleaved inside the cell by different types of enzymes as furin 
or proconvertases , by matrix metalloproteases (MMP; specifically MMP-3 
and MMP-7) or by plasmin giving the mature proteins( Chao and Bothwell, 
2002; Seidah et al, 1996 a,b). 
Then they all form non-covalent-linked homodimers where each monomer 
is approximately 13-15 Kda. 
About half of the amino acid residues in the mature protein are common to 
all neurotrophins and they all share six cysteine residues at identical 
positions.  
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This leads to the formation of the disulfide bridges and the similar tertiary 
structure of the molecules.  
Neurotrophins are all basic proteins with isoelectric points above 9.0. 
Because of the characteristic formation of a double loop formed by two 
disulphide bonds, in which a third disulphide bond is inserted, they are 
classed as part of the Cysteine Knot Superfamily (Ultsch et al, 1999). 
X-ray cristal structures revealed that the neurotrophins have a common 
structure: each monomer consists of seven beta strands (contributing to the 
three longitudinal antiparallel beta sheets) connected by three solvent-
exposed hairpin loops (loops 1, 2 and 4) and a longer loop (number 3) and 
contains three disulfide bridges between six fully conserved cysteine 
residues arranged in a cysteine-knot motif, which is characteristic of this 
growth factor superfamily (Narhi, 1993; Zhongcai et al, 2003). 
However in contrast to most of the other members of the superfamily, the 
neurotrophin monomers are arranged in the dimer in a parallel fashion, and 
are held together exclusively by non-covalent (mostly hydrophobic) 
interactions.  
All of the neurotrophins show different distributions through the peripheral 
nervous system and central nervous system with different and overlapping 
specificity towards the populations of sensory neurons of both neural crest 
and neural placode origin (Shelton et al, 1995; Ernfors et al, 1992). 
The expression of NTs in the brain is regulated during development.  
Highest levels of BDNF mRNA, NGF mRNA and NT-3 mRNA in the 
adult brain are found in the hippocampus, with 50 times more BDNF 
mRNA being present than NGF mRNA. 
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NT-3 is most abundantly expressed in the perinatal brain whereas in the 
adult brain its expression is significantly reduced.  
BDNF mRNA expression levels increase significantly in the first weeks 
after birth and even  in the adult brain BDNF is highly expressed, in 
particular the presence of great quantities was  noticed  in the hippocampus 
and the cortex. 
In the basal forebrain and hippocampus there are high levels of NGF but 
significant quantities can also be found  in other areas of CNS, spinal cord 
included. 
NT-4/5 is expressed most in the postnatal and adult hippocampus, 
neocortex and thalamic nuclei.  
Overall, BDNF seems to be more widely expressed than the other 
neurotrophins in the adult CNS.  
NT-3 is the most highly expressed in the immature CNS and its expression 
dramatically lowers down with maturation (Rantamaki T, 2006). 
In the central nervous system, neurotrophins are generally expressed by 
neurons however glial cells express as well NT-3 and NT-4/5. 
In situ hybridization has shown that two neurotrophins (brain-derived 
neurotrophic factor, BDNF; and neurotrophin 3, NT-3) and their specific 
high-affinity tyrosine kinase receptors (trkB and trkC) are expressed in the 
ear and its innervating sensory neurons (Pirvola et al, 1992). 
Several studies on various neurotrophins and neurotrophin receptor mutants 
have established a crucial role for these two neurotrophins and their 
receptors for the embryonic survival of the afferent innervation of the ear 
(Schimmang et al, 1995). 
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Brain-derived neurotrophic factor (BDNF) was originally purified from pig 
brain by Barde et al. in 1982.  
It is able to promote survival and differentiation of several populations of 
neurons, including mesencephalic dopaminergic neurons, motor neurons, 
and cholinergic neurons, and to protect them against neurotoxicity and 
ischemia (Binder and Scharfman, 2004). 
BDNF plays an important role in the nervous system regulating neuron 
survival and differentiation during development and postnatally 
maintaining its functionality (Bibel and Barde, 2000). 
Different BDNF mRNAs transcripts are localized and regulated differently 
indicating the biological significance of their existence.  
BDNF and all the neurotrophins exert their action through interactions with 
neuron cell surface receptors, whose two families have been identified: the 
high affinity and specific Trk receptors (KD ~ 10 -9), and a generic, lower 
affinity p75 receptor (KD ~ 10 -11) (Barbacid, M.; 1994). 
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1.5 Neurotrophin receptors 
Neurotrophins bind and activate two different types of transmembrane 
receptors: a high affinity one, which mediate their actions and a common 
low affinity one, whose function is still not completely clear, p75NTR. 
The Trk (tropomyosin related kinase) family consist of high-affinity  
(~10-11M dissociation constant) ligand-selective receptors. 
Despite the high similarity every neurotrophin is specific for a particular 
receptor: NGF binds primarily to TrkA, while BDNF and NT-4/5 to TrkB 
and NT-3 to TrkC. 
Probably NT-4/5 and BDNF interact with TrkB in distinct domains which 
gives BDNF a higher affinity to TrkB than NT-4/5 (Klein et al, 1991-
1992).  
NT-3 can also bind and activate TrkA and TrkB receptors, but with a much 
lower efficacy (Ip et al, 1993; Ryden and Ibanez, 1996). 
Both BDNF and neurotrophin NT4/5 induce TrkB autophosphorylation and 
so its activation (Ip et al, 1992; Fandl et al 1994). 
Tropomyosin related kinase receptors exist in different isoforms: trkA gene 
codes for two tyrosine kinase containing TrkA isoforms with just a 
difference of 6 aminoacids.  
trkB gene instead code for more than 8 different transcript products ranging 
in size from 0.7 to 9.0 kb which finally result in at least two types of 
receptors: full-length and truncated TrkB (Barbacid, 1994). 
Their extracellular regions are identical but truncated receptors lack the 
entire catalytic tyrosine kinase domain. 
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Localizations of NTs and their receptor genes in human 
genome 
chromosome protein References 
1q21-q22 TrkA  (Weier et al, 1995) 
9q22.1 TrkB  (Nakagawara et al, 1995) 
15q25 TrkC  (Valent et al, 1997) 
1p22 NGF (Francke et al, 1983) 
11p13 BDNF (Maisonpierre et al, 1991) 
12p13 NT-3 (Maisonpierre et al, 1991) 
19q13.3 NT-4/5 (Berkemeier et al, 1992) 
17q21-q22 p75NTR (Huebner et al, 1986) 
 
Two truncated TrkB receptors have been found in rodents, TrkB.T1 and 
TrkB.T2, of which TrkB.T1 is largely expressed in their brain (Baxter et al, 
1997), the same happens in human (Middlemas et al, 1991). 
Another member, TrkB.Shc, has been subsequently described in the human 
brain (Stoilov et al., 2002), but the two species isoforms’ are quite similar. 
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Figure 1.13 Alignment of peptide sequences of three human trks (Shelton et 
al, 1995) 
Neurotrophins actions are mediated by transmembrane full length Trk 
receptors possessing tyrosine kinase activity. 
Specifically NGF binds and activates primarily TrkA, BDNF and NT-4/5 
TrkB and NT-3 TrkC (fig.1.14). 
There are also truncated TrkB and TrkC receptors completely lacking the 
intracellular region and so the enzymatic domain, which is the signal 
transductor.  
All the neurotrophins also bind with equal affinity to a common low-
affinity (~10-9M dissociation constant) receptor, called p75NTR (Squinto et 
al., 1991). 
It was demonstrated that p75NTR (belonging to the tumour necrosis family 
receptor super family) has an important role in mediating Trk receptor 
signalling and, in the absence of neurotrophins, it may cause neuronal 
apoptosis. 
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Figure 1.14 The receptors for neurotrophins (taken from Rantamaki T., 
2006)  
 
 
Figure 1.15 TrkB protein (from DBB) 
 
In the central nervous system of the adults, TrkB and TrkC receptors can be 
found in the hippocampus and throughout the cortex, while TrkA is 
expressed mainly in the basal forebrain (Huang and Reichardt, 2001). 
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The full-length Trk receptors are predominantly of neuronal origin, 
truncated forms of these receptors are often expressed by non-neuronal 
cells like glia instead.  
Fritzsch in 1999 could show the differences in the expression patterns of 
the full-length and truncated TrkB receptors during development. 
Full-length TrkB in particular is expressed already perinatally while 
truncated TrkB starts to be expressed a few weeks later. 
Binding of BDNF to TrkB initiates dimerization and trans-
autophosphorylation of the tyrosine residues in the intracellular domain of 
the receptor (Reichardt, 2006). 
These phosphotyrosine residues act as docking sites for effector proteins 
that will trigger downstream signaling cascades, leading to various 
responses as the activation of protein kinase cascades, Ca2+ mobilization, 
and gene expression.  
BDNF activates TrkB receptors in the same or neighboring cells to promote 
their survival and may also enhance synaptic plasticity.  
Although TrkB levels change during development and show cell-specific 
expression patterns, not much is known about the mechanisms that regulate 
TrkB expression. 
At least four isoforms of trkB are produced by alternative splicing of the 
primary transcripts of the TrkB gene. 
Of these, only the full-length isoform, which contains an intracellular 
tyrosine kinase domain, is known to be capable of mediating BDNF 
signaling.  
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The other three truncated isoforms (T1, T2, and T-shc), which lack the 
intracellular kinase domain but possess the same extracellular BDNF 
binding domain as full length receptors, can also be generated by 
alternative splicing. 
T1 is prominently expressed in the brain and probably acts as a dominant 
negative inhibitor of BDNF signaling by forming heterodimers with full-
length trkB.  
Ten conserved phosphorylation-regulated tyrosine residues are present in 
Trk receptors intracellular region.  
After binding the dimeric ligand, Trk receptors dimerize itself and become 
autophosphorylated in trans in the intracellular catalytic domain. 
Moreover autophosphorylation at the Trk kinase domain may induce the 
phosphorylation of other tyrosine residues in the receptor.  
The phosphorylated tyrosines serve as docking sites for many of the 
intracellular enzymes and adaptors containing SH2 (Src homology) or PTB 
(phosphotyrosine binding domain) region (Huang and Reichardt, 2003). 
Following the phosphorylation of the tyrosine residue Y816 phospholipase-
Cγ1 (PLCγ1) is activated (Middlemas et al, 1994). 
Hydrolysing the phosphatidyl inositides (PI) of the membrane, activated 
PLCγ1 can generate inositol tris-phosphate (IP3) and diacylglycerol 
(DAG), two typical intracellular signalling messengers. 
IP3 increases [Ca2+]i by stimulating the release of Ca2+ from intracellular 
compartments so activating the signalling of a the intracellular Ca2+-
dependent molecules.  
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DAG activates DAG-dependent protein kinase-C isoforms, which in turn 
can regulate the ERK (extracellular signal-regulated kinase) signalling 
cascade. 
Phospho-Y515 is the docking site for Shc adaptor protein, which eventually 
activates Ras-ERK and PI3k-Akt cascades.  
BDNF effects are exerted: Ras-ERK pathway regulates neuronal 
differentiation and PI3k-Akt following events are important for cell 
survival and maintenance (Reichardt, 2006). 
 
Figure 1.16 Major intracellular signalling cascades regulated by 
neurotrophins. (taken from Rantamaki T, 2006) 
 
All Trk receptors are homologous in sequence, each comprising about 800 
amino acids with the amino terminal ~400 residues forming the 
extracellular portion of the receptor where binding of the neurotrophins 
takes place. 
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They are multidomain transmembrane proteins that consist of an 
extracellular ligand binding domain containing two cysteine rich regions 
separated by a leucine rich domain (Haniu et al, 1995), a transmembrane 
region, and a intracellular part with the juxtamembrane domain that 
includes a Shc binding site, a tyrosine kinase domain and a tail region 
containing a PLC-γ binding site. 
Although the precise three-dimensional structure of the entire extracellular 
fragment is not known, recognized sequence motifs have led to division of 
these receptors into five domains: one 3 tandem leucine-rich motif flanked 
by two cysteine cluster regions (domains 1-3,d1-d3) followed by two 
immunoglobulin domains (d4 and d5) of the C2 type belonging to the  
Immunoglobulin superfamily (Banfield et al, 2001). 
Trk B is one of the most widely distributed NTRs in the brain, whose 
expression is high in such areas as the neocortex, hippocampus, striatum, 
and brainstem. 
The second class of trk B receptors has the same extracellular and 
transmembrane domain as the other but contains a short cytoplasmic 
domain of 23 amino acids, lacking the entire kinase catalytic region. 
Although, the Trk B locus is widely expressed in the central nervous 
system and peripheral nervous system, not all the trk B transcripts are 
distributed equally. 
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Figure 1.17 TrkB expression (based on data from Su AI, Wiltshire T, 
Batalov S, et al (2004). "A gene atlas of the mouse and human protein-
encoding transcriptomes". Proc. Natl. Acad. Sci. U.S.A. 101 (16): 6062–7. 
 
Figure 1.18 TrkB expression (Shelton et al., 1995) 
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2. MATERIALS AND METHODS 
2.1 cDNA LIBRARY 
To get the cDNA library we used the Creator SMART cDNA Library 
Construction Kit by Clontech Laboratories Inc (Takara bio). 
This way we generated a full length cDNA Library from 1 µg of  poly A+ 
RNA, as shown in fig. 2.1. 
The library construction employed long-distance PCR (LD PCR; Barnes et 
al., 1994) for generating full-length cDNA. 
In this protocol a modified oligo(dT) primer (CDS III/3' PCR Primer) 
primed the first-strand synthesis reaction, and the SMART IV Oligo served 
as a short, extended template at the 5' end of the mRNA. 
When the RT reaches the 5' end, the enzyme’s terminal transferase activity 
adds a few additional nucleotides, primarily deoxycytidine, to the 3' end of 
the cDNA.  
The SMART IV Oligo, which has an oligo (G) sequence at its 3' end, base-
pairs with the deoxycytidine stretch, creating an extended template.  
RT then switches templates and continues replicating to the end of the 
oligonucleotide.  
The resulting full length ss cDNA contains the complete 5' end of the 
mRNA, as well as the sequence complementary to the SMART IV Oligo, 
which then serves as a universal priming site (SMART anchor) in the 
subsequent amplification by LD PCR (Chenchik et al., 1998).  
Only those ss cDNAs having a SMART anchor sequence at the 5' end can 
serve as a template and can be exponentially amplified.  
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Figure 2.1 Getting a cDNA library from RNApolyA+ (from Clontech kit) 
Incomplete cDNAs and cDNA transcribed from polyA+ RNA lack the 
SMART anchor so are not amplified. Thus, contamination by genomic 
DNA and poly A– RNA is eliminated.  
This selective amplification allowed me to construct a cDNA library with a 
high percentage of full-length clones using a microgram of poly A+ RNA. 
The next step in library construction was primer extension (Sambrook J. & 
Russell, D.W., 2001).  
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Similar to the first-strand cDNA synthesis described above, the CDS III/3' 
primer was used to prime the first-strand reaction, and the SMART IV 
Oligo served as a short, extended template at the 5' end of the mRNA. After 
first-strand cDNA synthesis, the primer-extension step generated full-
length, ds cDNA. 
2.1.1 FIRST-STRAND cDNA SYNTHESIS  
The following reagents were combined in a sterile microcentrifuge tube: 
• 1 µl RNA sample (1 µg poly A+RNA) 
• 1 µl SMART IV Oligonucleotide (12 µM) 
5'-AAGCAGTGGTATCAACGCAGAGTGGCCATTACGGCCGGG-3' 
• 1 µl CDS III/3' PCR Primer (12 µM) 
5'-ATTCTAGAGGCCGAGGCGGCCGACATG-d(T)30N–1N-3'          
(N = A, G, C, or T; N–1 = A, G, or C) 
deionized H2O was added to a total volume of 5 µl. 
The tube was spun briefly in a microcentrifuge and left incubating at 72ºC 
for 2 min, then it was cooled down on ice for 2 min and spun again to 
collect the contents at the bottom. 
To each reaction tube were added: 
2.0 µl 5X First-Strand Buffer  
• 250 mM Tris (pH 8.3) 
• 30 mM MgCl2 
• 375 mM KCl 
1.0 µl DTT (dithiothreitol, 20 mM) 
1.0 µl dNTP Mix (dATP, dCTP, dGTP, dTTP; 10 mM each) 
1.0 µl Super Script Reverse Transcriptase 2U/µl 
to a total volume  of 10.0 µl.  
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After mixing and pipetting ten times, the tube was incubated at 42ºC for 1 
hr and placed on ice to terminate first-strand synthesis. 
Then 1 µl of Sodium Hydroxide (25mM) was added to the tube (to degrade 
RNA). 
And it was left on ice after a incubation at 68ºC for 30 min. 
2.1.2 DOUBLE STRANDED cDNA SYNTHESIS BY PRIMER 
EXTENSION  
Preheated PCR thermal cycler has to be at 95ºC. 
11 µl First-Strand cDNA     
35 µl Deionized H2O 
50 µl 2X Taq pfu mix 
2 µl 5' PCR Primer (12 µM) 
5'-AAGCAGTGGTATCAACGCAGAGT-3' 
2 µl CDS III/3' PCR Primer (12 µM) 
5'-ATTCTAGAGGCCGAGGCGGCCGACATG-d(T)30N–1N-3' 
were mixed together to a total volume of 100 µl 
the content was gently mixed and collected by centrifugation at the bottom 
of the tube. 
PCR reaction : 
95ºC preheated 
72ºC 10 minutes 
95ºC 1 minute  
3 cycles 95ºC 15 seconds; 68ºC 8 minutes 
A 5-µl sample of the product was analyzed on a 1.1% agarose/EtBr gel, 
alongside a 1-kb DNA size marker. The ds cDNA appeared as a 0.1–9 kb 
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smear on the gel, with some bright bands probably corresponding to the 
abundant mRNAs for the brain. 
2.1.3 TRK B AMPLIFICATION 
Specific primers were designed, corresponding to the ATG and the TAG 
codon which represent in turn the start and the end of the gene: 
PCR reaction: 
F     5' ATGTCGTCCTGGATAAGGTGGC 3' 
R     5' CTAGCCTAGAATGTCCAGGTAG 3' 
 
2 X Taq polymerase mix* 50 µl 
Template (cDNA library ) 1  µl 
F primer (100mM) 1  µl 
R primer (100 mM) 1  µl 
dd water 47 µl  
Total 100 µl 
 
Taq+ mix 2X  
1 ml 10x buffer  
(100mM Tris-Cl pH 7.6 at 25ºC, 100mM MgCl2, 75mM DTT) 
200 µl Pfu 5U/µl  
30 µl cresol red dye 
250 µl dNTPs mix 40mM (10mM each) 
10% glycerol 
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Water up to 10 ml 
 
2X PCR MIX 10 ml 
200µl Taq 5U/µl 
2,5 ml sorbitol 2 M  
0,5 ml dNTPS 40mM  
0,6ml MgCl2 50mM  
2 ml Buffer 10X 
(670mM Tris-Cl; 150mM (NH4)2SO4; 0,1% tween20 pH 8.8) 
0,8 ml DMSO 
70 µl cresol red 
Water up to 10 ml 
 
PCR reaction  
95ºC 3 minutes 
3 cycles  
95ºC 1 minute 
55ºC 1 minute 
72ºC 2 minutes 
25 cycles  
95ºC 30 seconds 
60ºC 30 seconds 
72ºC 2 minutes 
Check on agarose gel 1.3% 
  
After proving that the gene amplified was actually TrkB full length (2469), 
the same PCR reaction was performed using a Taq polymerase mixed with 
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a Pfu polymerase which possesses 3' to 5' exonuclease proofreading 
activity in order to have nucleotide-misincorporation errors corrected. 
Then the polymerase-generated PCR fragment had to be treated with just 
Taq polymerase before being cloned into pGEM-T-easy vector in order to 
get a polyA overhang. 
So the purified PCR product was mixed with the 2X Taq mix and left  
at 95ºC 1 minute (denaturation step)  
and at 72ºC for 10 minutes (elongation step). 
An electrophoresis was performed and the band was excised from the gel, 
transferred to a tube with the binding buffer of the gel DNA purification kit 
(from Yorkshire Bioscience Ltd) and melted at 50-60 ºC. 
The fragment was purified with the specific spin columns and inserted into 
a cloning vector. 
 
2.1.4 INSERTION IN pGEM-T-Easy 
The fragment was ligated in pGEM-T-Easy from Promega, O/N 16ºC 
 
                Control ligation 
insert                       ---- 125ng 
pGEM-T-easy                      50ng 50ng 
T4 ligase                        3U 3U 
2Xligase mix (Promega) and water Up to           30µl Up to 30µl 
 
   PCR products generated using a nonproofreading DNA polymerase such 
as Taq DNA polymerase, which lacks 3´→5´ exonuclease activity, have a 
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single template-independent nucleotide at the 3´ end of the DNA strand 
(Newton and Graham, 1994).  
This single-nucleotide overhang, which is most commonly an A residue, 
allows hybridization with and cloning into pGEM-T vectors, which have a 
complementary 3´ single T overhang.  
We used the high-copy-number pGEM-T Easy Vector which contains T7 
and SP6 RNA polymerase promoters flanking a multiple cloning region 
within the coding region for the α-peptide of β-galactosidase.  
Inactivation by insertion of the α-peptide allows recombinant clones to be 
directly identified by colour screening on indicator plates containing X-Gal 
and IPTG.   
After ligation the incubation period was extended to 16 hours at 4ºC in 
order to increase the number of colonies after transformation.  
 
Figure 2.2 pGEM-T-Easy Vector (Promega) 
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2.1.5 DNA CONCENTRATION 
DNA was precipitated adding 1 µl glycogen and 2,5 volumes of 96% 
Ethanol, left in a tube at -70ºC for an hours, centrifuged at 13.5 K rpm in a 
bench centrifuge. 
The supernatant was discarded and the pellet was left to dry, then a small 
amount of ddH2O was added. 
 
2.1.6 ELECTROTRANSFORMATION 
E.coli DH5α electrocompetent cells were thawed on ice and circa 50 µl 
were added to the DNA (in a pre-chilled centrifuge tube). 
After mixing, cell suspension was transferred into a precooled cuvette 
which has two aluminium electrodes on its sides and put in the 
electroporator. 
After the 0.5 seconds pulse the suspension was immediately transferred 
into a tube with prewarmed SOC medium which is made of 
• 2% w/v bacto-tryptone  
• 0,5% w/v bacto-yeast extract  
• 10mM NaCl  
• 2,5mM KCl  
• ddH2O to 1000 mL 
Added fresh 
• 10mM MgCl2  
• 20mM glucose 
 
and left in the orbital shaker at 37ºC for about an hour before plating  about 
100 µl onto LB agar Carbenicillin( Cb ) plates 100µg/ml. 
White colonies were chosen and an analysis of recombinant vectors by 
colony PCR and restriction enzyme digestion had to be performed because 
in pGEM-T vectors the insert can be cloned in either direction but just one 
is the correct one for transcription and translation of the gene. 
Either a colony PCR with internal primers was done. 
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F in 5' GGGAACATCTCTCGGTCTATGC 3' 
R in 5' GCCAAACTTGGAGTGTCTTGCC 3' 
 
To mend the mutations found in Trk B it had to be cut from pGEM-T easy, 
made blunt and inserted in pBluescript KS +(pBSK) from Stratagene. 
To get the proper amount of DNA we inoculated bacteria from a single 
colony obtained with a transformation of the original plasmid and grew it 
overnight in LB-Carbenicillin. Purification with the plasmid DNA 
purification kit from Yorkshire Bioscience followed. 
VECTOR DIGESTION 
TrkB in pGEM-T-easy 0,5 µg 
Eco RI 2 units 
Buffer Eco RI 10 µl 
Dd water Up to100 µl 
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Figure 2.3 pBluescript vector from Stratagene and the multiple cloning site 
(598-826 in the sequence) 
pBluescript(+) was cut with the restriction enzymes Hind III and Bam HI 
O/N 37ºC  to eliminate Hind III site in its MCS (multiple cloning site) and 
made blunt, too. 
Cutting Bam HI – Hind III fragment 
For this purpose 0.5 µg of DNA clone were separately digested with: 
 2 units of BamHI (G▼GATCC; Amersham Pharmacia Biotech) in 20 mM 
Tris-HCl pH 8.5, 10 mM MgCl2, 1 mM dithiothreitiol, 100 mM KCl;  
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and 2 units of HindIII (A▼AGCTT; Amersham Pharmacia Biotech) in 10 
mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM dithiothreitiol, 50 mM NaCl; 
in 25 µl of reaction mix, incubated for 1 h at 37°C 
 
• Getting both TrkB fragment and 
pBluescript (+) blunt 
• 2X Taq mix was added to both DNA 
solution 
• 95ºC 1 minute 
• 72 C 10 minutes 
• then 4ºC. 
 
 
TrkB insertion into pBluescript (+) O/N 16ºC 
TrkB cDNA was ligated into pBluescript (+)  cloning vector, with 2u of T4 
ligase (NEB) in 50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM 
Dithiothreitol pH 7.5, at 16ºC over night. 
2.1.6 CHEMICAL TRANSFORMATION 
Chemical competent cells from Novagen were thawed on ice, the ligation 
mix was in a pre-chilled tube on ice. 
After mixing them together, the cell suspension was left 10 minutes on ice, 
then heat shocked at 42ºC for 30 seconds and immediately put on ice for 2 
minutes before transferring it all in a tube containing 250  µl SOC. 
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Cells were left shaking (220 rpm) at 37ºC for about an hour and then 100 µl 
were plated on LB-Cb agar dishes. 
Cutting TrkB pBSK(+) HindIII/NdeI 
For this purpose 0.5 µg of DNA clone were separately digested with: 
2 units of HindIII (A▼AGCTT; Amersham Pharmacia Biotech) in 10 mM 
Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM dithiothreitiol, 50 mM NaCl;  
and 2 units of NdeI (CA▼TATG; Amersham Pharmacia Biotech) in 20 
mM Tris-acetate, 50 mM potassium acetate, 10 mM Magnesium Acetate, 1 
mM Dithiothreitol pH 7.9 in 25 µl of reaction mix, incubated for 1 h at 
37°C 
Getting pBSK(+) blunt  
pBSK(+) 0.5 µg 
Blunting enzyme Fermentas 2 units 
2X reaction Buffer 20 µl 
Water Up to 40 µl 
After reinserting TrkB fragment into pBluescript with a ligation a site 
specific mutagenesis was performed cutting the 657 bp fragment in which 
both the mutations were found with two appropriate restriction enzymes: 
Hind III and Nde I and inserting it into a pGEM-T easy vector. 
To mend mutations 6 primers were synthesized: 
F pre Hind 5' GCATTTCCGATTGGAGCCTAAC 3' 
R post Nde 5' CTACAAGATTTTCCGCCACACAAG 3' 
and 
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Mut 1 f  5' CATTTCTGAAAAACAGCAACCTGC 3' 
Mut 1 r  5' GCAGGTTGCTGTTTTTCAGAAATG 3' 
Mut 2 f  5' GCAGATACCCAATTGTGGTTTGC 3' 
Mut 2 r 5' GCAAACCACAATTGGGTATCTGC 3' 
After several amplifications the mutations were eventually mended as the 
sequencing reaction with many internal primers confirmed.  
trkB s1F 5’ GTGGAGGAAGGAAAGTCTATC 3’  
trkB s1R 5’GGATCACCTGCCACACTAC 3’ 
trkB s2F 5’GGTCTATGCTGTGGTGGTG 3’ 
trkB s2R 5’CACCACCACAGCATAGACC 3’ 
trkB s3F 5’CGTCTGCGTGGAGGGCG 3’ 
trkB s3R 5’TGGAGGTTGGTCAGGAGC 3’ 
In the first step mutation number one was fixed using as a template the 
final products of  F pre Hind – Mut1 R  and Mut1F- R post Nde PCR 
reactions 
After checking the sequencing results the second step gave the whole 
fragment aligning with the natural TrkB receptor performing a PCR 
reaction with F preHind-R postNde and using as a template the products of 
F pre Hind-Mut2 r and Mut2 F-R postNde. 
 
2.1.7 REINSERTION OF THE TRKB FRAGMENT INTO FULL 
LENGHT TRKB 
The fragment with the two fixed mutations was then cut from pBSK with 
Hind III and Nde I and reinserted into the pGEM-TrkB. 
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After several attempts the gene was complete and so we tried to insert it 
into a prokaryotic expression vector (pET29) in order to have it produced 
in a large amount by bacteria. 
Results were not good as the whole gene was probably too large and in any 
case too difficult to produce via bacteria because of its chemical nature. 
Being a transmembrane receptor means that the protein has either a 
hydrophobic and a polar nature, not mentioning that it needs many post-
translational modifications to be active, and these are not feasible by 
bacteria. 
2.2 INSERTING TRKB FL INTO PCDNA3.1 
 
 
Figure 2.4 pcDNA3.1 (adapted from stanxterm.aecom.yu.edu) 
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pcDNA 3.1 was chosen as it could be transfected into eukaryotic cells. 
Being TrkB gene human, it would be much better performing a phage 
display on eukaryotic cells as, in contrast with bacteria, they can provide 
the required post-translational modifications to the receptor. 
After the transformation 3 clones resulted positive to the colony PCR and 
have been transfected, proving their efficiency. 
To obtain the green fluorescent protein (GFP) thus making TrkB traceable 
in transfected cells, two suitable primers were designed: 
F egfp Bam 5’CTTGGATCCGACATGGTGAGCAAG 3’ 
R egfp Bam 5’ACGGATCCCTTGTACAGCTCGTCC 3’ 
After obtaining GFP gene from an old construct, it was amplified and 
digestion with the restriction enzyme Bam HI for both the vector and insert 
(pcDNA3.1-TrkBfl) followed. An overnight ligation at 16ºC was 
performed. 
Cells were actually transfected using Jet Pei from Polyplus. 
A cell line derived from human cervical cancer (HeLa) was used. 
2.2.1 CELL CULTURE 
Cells were cultured in a 37ºC and 5% CO2 incubator, in medium 
containing:  
• DMEM (Dulbecco Modified Eagles’s Medium): 
• 10% FBS (Fetal Bovine Serum); 
• 5% HS (Horse Serum); 
• 1% PS (Penicillline-Streptomycine); 
• L-Glutammine 2mM.  
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2.2.2 TRANSFECTION 
Cells were grown in six wells plates containing glass coverslips till they 
reached a confluence around 50-70% and then transfected using JetPEI. 
jetPEI™ compacts DNA into positively charged particles - called 
complexes - capable of interacting with anionic proteoglycans at the cell 
surface.  
Upon binding to the cell membrane, the complexes are internalized via 
endocytosis. Once inside the endosomal compartment, the DNA is 
protected from degradation by jetPEI™. This is in part due to the unique 
property of this polymer to act as a "proton sponge", which in turn buffers 
the pH within the endosome.  
This mechanism ultimately cause the breaking of the endosome and the 
release of the DNA and the complexes into the cytoplasm, thereby allowing 
nuclear transport for subsequent transcription. 
Transfection procedure in a 6-well plate: 
Per well, 3  µg of DNA were diluted in 150 mM NaCl to a final volume of 
100 µl, mixed gently and spun down briefly. 
The same was done with 6 µl of jetPEI™ per well. They were diluted in 
150 mM NaCl to a final volume of 100 µl. Vortexed and spun down 
briefly. 
The 100 µl jetPEI™ solution was added to the 100 µl DNA solution in the 
following order: 
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Figure 2.5 Transfection with jetPEI 
The solution was vortexed immediately and spun down briefly. 
A 15 to 30 minutes incubation at room temperature followed. 
The 200 µl jetPEI™/DNA mix was added dropwise to the cells in 1 ml of 
serum-containing medium. The plate was then gently swirled to 
homogenize.  
The next day, the medium was changed and immunofluorescence was 
performed within 24 to 48h following transfection. 
 
2.2.3 IMMUNOCYTOLOGY ASSAY 
Cells on the coverslips were washed in PBS and fixed in paraformaldehyde 
4% in PBS 1X for half an hour at room temperature. 
After washing with PBS cells were permeabilized with PBS-Tween20 
0.1% for 15 minutes at room temperature. 
A blocking buffer made with 5% goat serum in PBS was then added for 30 
minutes at 37ºC in order to block aspecific sites. 
Subsequently cells were left in a 1% solution of the primary antibody (anti 
TrkB rabbit polyclonal IgG, from Santa Cruz with the epitope 
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corresponding to amino acids 160-340 mapping within the extracellular 
domain of TrkB of human origin) in PBS overnight at 4ºC. 
On the next day, following PBS washes cells were incubated in the dark at 
room temperature for 45 minutes with the secondary antibody diluted in 
PBS at different concentrations. 
Secondary antibody from Santa Cruz biotechnology Inc., California was 
raised in goat and FITC conjugated. 
Pictures were taken using a NIKON fluorescence microscope at a 
wavelength of 494 nm. 
 
2.2.4 IMMUNOHISTOCHEMISTRY ASSAY 
To check the effectiveness of the antibody some immunohistochemical 
assays on cochleas' sections were made. 
The cochlea sections from rat, mouse and guinea pig were stained using 
Vectastain ABC kit from Vector Laboratories. 
The paraffin embedded section slides were dipped into xylene and ethanol 
solutions at various concentrations and then washed in water and PBS. 
After permeabilizing with PBS and Triton 0.1%, slides were covered with 
the blocking buffer  for 40 minutes and then left overnight with the primary 
antibody at 4ºC in a humidified chamber. 
The next day the primary antibody was washed away and an incubation of 
30 minutes with the secondary antibody at room temperature in the dark 
followed.  
The secondary antibody was detected with the avidin - biotin complex 
technique using a Vectastain Elite ABC kit ( from Vector Laboratories, 
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CA) and developed with DAB (diaminobenzidine) from the same 
company. 
Pictures were acquired with an eclipse 80i Nikon Microscope. 
 
2.2.5 TRKB BINDING DOMAIN 
PCR using the whole gene as a template was performed with these two 
primers 
F2 5' CGCATATGGCACCAACTATCACATTTCTCGAATCTC 3' 
R2 5' GCGGATCCCTATTAATGTTCCCGACCGGTTTTATC 3' 
The PCR product was subcloned into pET15b to create the expression 
vector pET15b-TrkBIg2. 
The amino acid residues from 286 to 430 comprise a second Ig-like domain 
of TrkB which has a beta sandwich structure.  
In addition there are a further 21 residues at the NH2 terminus, which 
constitute the histidine tag and associated thrombin cleavage sequence.  
Chemical transformation was done using a special E.coli strain, 
BL21(DE3)pLysS, which is especially meant for the expression of  proteins 
and produce themselves lisozyme. 
Expression was carried out in accordance with the pET (Novagen) manual. 
Cells were grown in LB (10 g of NaCl; 10 g of tryptone; 5 g of yeast 
extract; in 1L  deionized H2O) in two-litre flasks shaking at about 160 rpm 
in the orbital shaker at 37ºC till they reached  an O.D. comprised between 
0,4 and 1 (more or less 3 hours). 
Protein expression was induced with addition of 1 mM IPTG, for about 3-4 
hours. 
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Harvested cells were resuspended in 10% glycerol and frozen at -80ºC.  
Expression of the protein was checked at different time with SDS PAGE 
analysis according to the Criterion manual from BioRad. 
Pellets were frozen and thawed to let the lysozyme work and then sonicated 
for about 500 seconds, then washed with different solutions. 
Solution 1  
• 20 mM sodium phosphate buffers (pH 8-8.5)  
• 0.1% Triton X-100  
• 0.1 M NaCl  
centrifuged at 4ºC for 30-60 minutes 4500 rpm 
Solution 2 (3 washes) 
• 20 mM sodium phosphate buffers (pH 8-8.5)  
• 1% Triton X-100  
• 0.1 M NaCl  
centrifuged at 4ºC for 30-60 minutes 4500 rpm 
Solution 3 (3 washes) 
• 20 mM sodium phosphate buffers (pH 8-8.5)  
• 1% Triton X-100  
• 1 M NaCl  
centrifuged at 4ºC for 30-60 minutes 4500 rpm 
These washes removed all soluble matter, leaving inclusion bodies 
containing insoluble protein, while the centrifugation helped avoiding 
clogging of protein aggregates or cell debris on the Ni-NTA column. 
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2.2.6 PURIFICATION ON NI-NTA GEL 
Purified inclusion bodies were solubilised in 8 M urea buffer (20 mM 
sodium phosphate, pH 8.5, 1 mM DTT) and incubated at room temperature 
for 2-24h with gentle shaking. TrkBIg2 protein was purified on a His-Select 
Nickel Affinity Gel from Sigma. 
This is an immobilized metal-ion affinity chromatography (IMAC) product 
consisting of a quadridentate chelate on beaded agarose charged with 
nickel that is designed to specifically bind histidine containing proteins.  
HIS-Select Nickel Affinity matrix is 6% beaded agarose and is selective for 
recombinant proteins with histidine tags while it has a low non-specific 
binding of other proteins. 
The affinity gel was poured into a clean chromatography column, washed 
with 1–2 volumes of deionized water to remove the ethanol storage 
solution and then equilibrated with 3–5 volumes of equilibration buffer. 
 
Figure 2.6   The interaction between Ni-Nta beads and the Histidine tag 
(from Qiagen Qiaexpressionist) 
Purification was carried out under reducing conditions (20 mM sodium 
phosphate, pH 8.5, 8 M urea, 10 mM imidazole), and eluted using 300 mM 
imidazole after defining the best concentration for the elution. 
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2.2.7 SDS PAGE   
After the elution on Ni-Nta column and the gel filtration   other SDS PAGE 
assays were performed following the Criterion Manual instructions, so 
running buffer (1x 25 mM Tris; 192 mM glycine; 0.1% SDS) and loading 
buffer ( 62.5 mM Tris-HCl, pH 6.8; 2% SDS; 25% glycerol; 0.01% 
Bromophenol Blue; 350 mM DTT) were prepared. 
 
Figure 2.7 SDS PAGE vertical gel (from http://web.chemistry.gatech) 
 
An unstained molecular weight marker was purchased from Fermentas with 
bands at 116; 66.2; 45; 35; 25; 18.4; 14.4 Kda. The molecular weight 
marker was heated for 5 minutes at 95ºC while samples – after being 
diluted in the loading buffer – were heated at 65ºC for 20 minutes as the 
protein could be damaged by such a high temperature. 
The different samples were then loaded on a precast Criterion Tris-HCl 
gradient gel 10-20% from Bio-Rad which provides the best resolutions for 
proteins weighing 10-100KDa. 
After the running step – generally performed overnight with a low constant 
voltage–gel was washed three times with deionized water for at least 15 
minutes to remove SDS and dyes.  
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About 50 ml of the staining solution (Bio-Safe Coomassie from BioRad) 
were added and left incubating for 30-60 minutes shaking from time to 
time. 
In the destaining step the gel was washed in water for an extended period 
(either overnight, or over a couple of days) to get a better resolution.   
 
2.2.8 REFOLDING 
Refolding took place under nonreducing conditions (20 mM sodium 
phosphate, pH 8.5, 100 mM NaCl) on a Superdex 200 gel-filtration column 
(Amersham bioscience). 
Superdex prep grade is a preparative gel filtration medium with a 
composite matrix of dextran and agarose. This matrix (fig 2.8) combines 
the gel filtration properties of cross-linked dextran (Sephadex) with the 
physical and chemical stabilities of highly cross-linked agarose, providing 
high selectivity and resolution.  
 
Figure 2.8 Hypothetical view of a section through a bead from Superdex 
(Amersham  Bioscience) whose mean particle size is 34µm. 
 
150 ml of the Superdex 200 slurry were poured into a XK 26/40 column 
avoiding bubbles. Void volume (61 ml circa) was calculated loading a 
saturated solution of bromophenol blue and blue dextran (see figure). 
 61 
 
Figure 2.9 Experimental measure of the void volume in the gel filtration 
column  
 
Fractions eluted from the NiNta column were concentrated with an Amicon 
Ultra centrifugal filter device, 5.000 NMWL . 
The tubes were spun at 2000g for about 45-60 
minutes and concentrated to the final volume of 2-
3 ml maximum. 
Flow rate was approximately 1.50 ml/minute. 
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Figure 2.10 Gel filtration technique 
The presence of the protein in the fractions was checked mixing some 
microliters of Biosafe staining solution with the eluted and comparing it 
with a known concentration of BSA and coomassie. 
 
Figure 2.11 Checking the presence of BSA protein in the fractions eluted 
from the superdex column 
 
TrkBIg2 monomer was found in fractions collected 100-130 ml after 
loading the sample. 
Separation from dimer and aggregate was finally achieved as it was 
demonstrated further.   
 63 
An SDS PAGE and a native PAGE gel were ran to confirm the presence of 
TrkB binding domain, fractions from the peak corresponding to a 
molecular weight of approximately 18.5 kDa actually contained TrkBIg2 
monomer. 
For the native gel, proteins were prepared in a nonreducing, nondenaturing 
sample buffer that maintained the proteins’ secondary structure and native 
charge density. All the conditions were the same as before apart from the 
fact that DTT and SDS were not used. 
PHAGE DISPLAY  
Phage display is a selection technique in which a library of  bacteriophages, 
each displaying a different peptide sequence, is exposed to an immobilized 
target (Smith and Petrenko, 1997; Arap, 2005) 
After the incubation the unbound phage is washed away while specifically 
bound phages stick to the target. 
Elution of the phages from the receptor is done washing with an excess of 
its natural ligand . 
Phages eluted from the target are used to infect bacteria and thus be 
amplified, this process has to be repeated at least 3 or 4 times. 
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Figure 2.12 The phage display technique in brief 
 
Single colonies are then chosen isolated and sequenced. 
2.2.7 THROMBIN CLEAVAGE 
Fractions eluted from the gel filtration column containing TrkBIg2 were 
incubated with Ni-Nta gel, phages and thrombin (from Sigma) in a solution 
containing 20 mM Tris-Cl, 150 mM NaCl, pH 8.4. 
The protein is fused with a His tag and presents a cleavage site for 
thrombin before the actual binding domain. 
 
Figure 2.13 Thrombin Cleavage site in pET-15b 
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To this effect only the phages actually attached to the protein can be 
washed away and eluted after thrombin’s cut, while the beads and the His 
tag will remain in the tube. 
 
2.3 BDNF 
Concerning brain derived neurothrophic factor we followed more or less 
the same scheme as the one used for TrkB. 
We obtained the gene from the same human brain cDNA library using the 
specific primers: 
F 5’ATGACCATCCTTTTCCTTAC 3’ 
R 5’CTATCTTCCCCTTTTAATGG 3’ 
With a PCR reaction with Taq polymerase 
95ºC 3 minutes 
3 cycles  
95ºC 1 minute 
55ºC 1 minute 
72ºC 1 minute 
25 cycles  
95ºC 30 seconds 
60ºC 30 seconds 
72ºC 40seconds 
Checked on agarose gel 1.3% (as in figure, band at 744bp) 
After confirming the size of the neurothrophin gene and amplifying it with 
Taq/Pfu polymerases mix we inserted it into pGEM-T-easy with the 
technique of T/A cloning. 
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We then inserted the gene into pet28 and transformed BL21(DE3)pLysS 
cells from Novagen, following PET manual to obtain the expression of the 
protein. 
We checked translatability of BDNF codons in E.coli with a program based 
on codons usage in bacteria found on the website 
http://www.faculty.ucr.edu/~mmaduro/codonusage/usage.htmtranslated 
and the fraction of sense codons below threshold (=10.00):was 60/247 
(24%), as in figure. 
Colors: = less than 10% of codons for same amino acid; = at least 10% 
Figure 2.14 E.coli codon usage analysis 
 A new BDNF gene was synthesized using five different primers each about 
100bp long which included two suitable restriction sites, a histidine tag, a 
thrombin cleavage site and the ribosome binding site (RBS). 
The 100-mers, HPLC purified were provided by Yorkshire Bioscience 
BDNF – F1  
5'TATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCG
GCCTGGTGCCGCGCGGCAGCCACTCCGACCCGGCTCGTCGTGGT
GAACTGTCCGTTTG 3’ 
BDNF – F2  
5’GGCTCGTCGTGGTGAACTGTCCGTTTGCGACTCCATCTCCGAA
TGGGTTACCGCTGCTGACAAAAAAACCGCTGTTGACATGTCCGG
TGGTACCGTTACCTTC 3’ 
BDNF –F3  
5’GTCCGGTGGTACCGTTACCGTTCTGGAAAAAGTTCCGGTTTCC
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AAAGGTCAGCTGAAACAGTACTTCTACGAAACCAAATGCAACCC
GATGGGTTACACC 3’  
BDNF –F4  
5’GCAACCCGATGGGTTACACCAAAGAAGGTTGCCGTGGTATCG
ACAAACGTCACTGGAACTCCCAGTGCCGTACCACCCAGTCCTAC
GTTCGTGCTCTGACTATGG 3’ 
BDNF –F5  
5’CGTTCGTGCTCTGACTATGGACTCCAAAAAACGTATCGGTTGG
CGTTTCATCCGTATCGACACCTCCTGCGTTTGCA  
CCCTGACCATCAAACGTGGTCGTTAGCTCGAGAC 3’ 
The amplification of this brand new gene was performed in successive 
steps and the final product was inserted into a pGEM-T-easy vector. 
Two mutations were detected therefore a mutagenesis had to be done with 
the undermentioned primers: 
Fix first mut F: 5’CGAATGGGTTACCGCTGCTGACAAAAAAAC 3’ 
Fix first  mut R: 5’GAGATGGAGTCGCAAACGGACAGTTCACC 3’ 
Fix second mut F: 5’TTTGCACCCTGACCATCAAACGTG 3’ 
Fix second mut r: 5’CGCAGGAGGTGTCGATACGGATG 3’ 
Afterwards BDNF was inserted into pET28a and expressed by E.coli cells. 
As for TrkBIg2 purification inclusion bodies were collected after 
harvesting and sonicating the biomass. 
Clarified inclusion bodies were poured into a Ni-nta column and the protein 
was finally eluted washing with an imidazole solution (200mM). 
The most suitable refolding strategy is under evaluation. 
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2.4 PHAGE DISPLAY ON GUINEA PIGS 
Guinea pigs were chosen as models for the in vivo phage display as they 
had bigger ears and cochleas thus resulting easier to handle. 
Caviae at different ages were weighed (400-800g), anesthetized and 
shaved. 
Behind the ear, an incision was cut allowing the surgeon to operate. 
A cochleostomy was done with the subsequent injection of 10 µl phages 
into the perilymphatic space through the round window membrane. 
The hole was closed with some tissue and dental cement. 
After 15-45 minutes the animals were sacrificed and cochleas explanted. 
They were washed in different solutions of water, TBS (50 mM Tris-HCl 
(pH 7.5), 150 mM NaCl) and TBS Tween and dried with a gauze. 
After putting the cochleas in a tube they were smashed and crashed with a 
pestle and incubated with glycine chloride buffer for 5 minutes at room 
temperature. 
The supernatant was taken after centrifuging on a bench centrifuge at 
10krpm (rotation per minute) and a solution of Tris at pH 8.9 was added. 
Titering followed. 
About 100µl were used to infect 300ml bacteria cells in LB in their log 
phase. 
Biomass was grown in an orbital shaker at 37 ºC for 3-4 hours and 0.5 ml 
chloroform were added. 
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Following centrifugation the supernatant was collected and mixed with 1/6 
volumes of PEG-NaCl (20% (w/v) polyethylene glycol–8000, 2.5 M 
NaCl). 
A succession of centrifugations and resuspensions in TBS and PEGNaCl 
was performed resulting in a final pellet containing the amplified phages. 
These phages after being titered could be used to start a new round of the 
selection. 
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3 RESULTS AND DISCUSSION 
 
The neurotrophic factors are released by neuronal target tissue in order to 
regulate differentiation of the neurons during development and assure their 
survival throughout adult life (Maness et al. 1994; Terenghi; 1999). 
Furthermore it has been demonstrated that neurotrophins could promote 
nerve survival after an injury (Gillespie et al., 2002) which makes them 
potential therapeutic agents against neurodegeneration. 
Brain derived neurotrophic factor is also of vital importance for neuron 
survival and especially in the inner ear, as its absence leads to an almost 
complete loss of innervation and consequently, functionality (Fritzsch et al 
1997). 
The binding of this neurotrophic factor to its natural receptor TrkB triggers 
signalling which is crucial for axonal outgrowth, neuronal survival, 
neurotransmitter release and synaptic plasticity. 
It may be therefore of great help in people affected by sensorineural 
hearing loss and using cochlear implants, as it has already been 
demonstrated that it maintains neuronal cells alive and this proved to be 
necessary for the efficacy of the prosthesis. 
I joined a European project which is working at the creation of 
multifunctional nanoparticles that could be used as drug carriers for a target 
delivery, in particular in spiral ganglion neural cells in the ear. 
BDNF could direct nanoparticles to this target when binding to its specific 
neuronal transmembrane receptor TrkB. 
 The issue with its application is related to its big size that makes it difficult 
to deliver it. 
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Our aim was then to find some smaller peptides mimicking BDNF action 
and affinity for its receptor TrkB in order to attach them to these new 
generation nanoparticles and direct them to their cellular target. 
As our goal was attaining BDNF mimetic peptides, we worked to get its 
full length receptor purified in order to perform the phage display on it. 
Our starting material was a polyA+ RNA library from human adult brain 
from which we could finally obtain TrkB gene with the PCR having 
designed the proper primers. 
After subcloning it into a cloning vector and fixing the mutations occurred 
during the DNA amplification, we finally inserted it in a prokaryotic 
expression vector. 
Due to its transmembrane protein nature, though, expression in bacteria 
proved to be very complex and difficult. 
The coexistence of the hydrophobic and hydrophilic domains makes the 
production of the protein almost impossible for prokaryotic cells. 
This fact forced us to find a different solution. 
We obtained a cDNA library from RNA polyA+ from the whole adult 
human brain using Creator SMART cDNA Library Construction Kit. 
Our aim was getting the gene coding for the tyrosine kinase receptor TrkB 
as it was the target of the phage display. 
Random peptides 12-mers expressed at the N-terminus of a minor coat 
protein of the M13 phage have to stick to the receptor binding domain 
(Smith, G.P. and Scott, J.K.; 1993).  
This domain is exposed outside the cell thus in the extracellular domain of 
the protein. 
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In our study we also needed the intracellular kinase domain as we wanted 
to check the efficacy of the interaction after the binding. 
Investigating in literature I found many different isoforms of TrkB gene 
(Klein et al 1989, 1990) according to the type of tissue they were expressed 
and I chose the one representing the full length receptor. 
Despite the fact it was longer than the other variants we decided to go for it 
as we also wanted the protein structure to be the closest possible to the 
natural one expressed in the neurons of the spiral ganglion  in the inner ear.  
In literature the sequence 2469 bp (base pair) long was selected: it codes 
for the full length functional receptor for brain derived neurotrophic factor 
(Shelton et al., 1995). 
All three domains are represented in this 822 aminoacids long protein: the 
extracellular domain, the single transmembrane segment and the 
intracellular one possessing a tyrosine-kinase fragment (Shelton et al., 
1995) 
 
 
Figure 3.1 TrkB on the gel, 2469 bp. 
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Specific primers based on the coding sequence were designed, the forward 
one called F1 including the three bases corresponding to the start of the 
gene and the reverse one starting from the TAG codon which represent the 
end of the gene (R1).  
Using 1µg of the cDNA library taken from human brain as a template a 
number of polymerase chain reactions were performed in order to amplify 
the gene sequence and so get a good amount of the DNA. 
After getting the DNA and checking the size of it on gel (2469 bp as shown 
in figure 3.1) we subcloned it into a pGEM-T-Easy vector with the method 
of the T/A cloning.       
PCR products generated using a nonproofreading DNA polymerase such as 
Taq DNA polymerase, which lacks 3´→5´ exonuclease activity, have a 
single template-independent nucleotide at the 3´ end of the DNA strand.  
 
 
Figure 3.2 TrkB full length in pGEM-T-easy 
 
The best of the clones was aligning with TrkB but presented three 
mutations at 343, 578, 2337 bases (see figure 3.2). 
One of the mutations (at 2337) was not significative as it did not affect the 
final translation into protein whereas the other two had to be fixed. 
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With a site specific mutagenesis the mutations were eventually mended and 
the fragment (fig.3.3) cut with the appropriate restriction enzymes could be 
reinserted into the original pGEM-T easy vector containing the other part 
of the gene. 
 
 
Figure 3.3 Position of mutations and primers in TrkB full length 
After several attempts the gene was complete and so we tried to insert it 
into a prokaryotic expression vector (pET29) that allowed to get a large 
amount of the protein which is the target of the phage display. 
Results were not good as the whole gene was probably too large and in any 
case too difficult to produce via bacteria because of its chemical nature. 
Being a transmembrane receptor infact, means that the protein has either a 
hydrophobic and a polar nature, not mentioning that it needs many post-
translational modifications to be active, and these are not feasible by 
bacteria. 
In literature I could find numerous studies aiming at determining which 
part of the TrkB extracellular domain was specific for the neurotrophin 
binding.  
The LRMs of TrkA and TrkB have been reported as essential for ligand 
binding, in particular the second LRM. Many studies demonstrated that 
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interaction with the Ig-like domains of TrkA is crucial for NGF binding 
(Ultsch, M H et al., 1999; Urfer et al, 1995). 
In particular the second Ig-like domain, closest to the transmembrane-
spanning region, provides the main contact for both NGF binding to TrkA 
and NT3 binding to TrkC (Urfer et al, 1998). 
In various articles (Haniu et al, 1997; Naylor et al, 2002) it was 
demonstrated that the actual binding domain of the receptor is a small part 
of the protein spanning from nucleotides 953 to 1397 of the human TrkB 
gene, which corresponds to amino acid residues 286 to 430 of the mature 
protein 
Naylor et al. (2002), fully proved the efficacy of the ligand binding with 
surface plasmon resonance assays so confirming that the second Ig-like 
domain of TrkB is the main docking region for BDNF. So we designed 
new primers to obtain only the binding domain from the whole gene. After 
subcloning the PCR product we created the expression vector pET15b-
TrkBIg2.  
The plasmid contained an N-terminal His-tag with an adjacent thrombin 
cleavage site. 
This enabled an easier purification of the protein with a commonly used 
technique in which recombinant proteins tagged with 6-10 poly Histidines 
can be purified in one step by ion metal affinity chromatography (IMAC) 
as described in Porath et al., 1975. 
This purification method takes advantage of the fact that several metal ions, 
and in particular Nickel and Cobalt exhibit affinity to Histidine residues 
(Schmitt, J., Hess, H., and Stunneberg, H.G.; 1993; Lindner et al, 1992) . 
Transformation was done using a special E.coli strain, BL21(DE3)pLysS, 
especially meant for the expression of proteins: they in fact produce 
themselves lisozyme allowing their own degradation, in practice.  
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The presence of the protein and the best parameters for bacteria induction 
and washing were checked every time, step by step with SDS PAGE assays 
as shown in fig 3.4.confirming the data of a previous article by Naylor et 
al.; 2002 (see fig.3.4)  
 
Figure 3.4 TrkBIg2 expression in different clones. Lanes 1 to 4, 7and 8 
uninduced cells, time zero. Lanes 5, 6, 9, 10 expression after 2 hours 
induction with IPTG, 11 BL21(DE 3)pLysS not transformed with the 
plasmid pET15b- TrkBIg2, 12 molecular weight marker, lanes 13 to 18 
expression after 24 hours induction. 
 
Bacteria had expressed the protein TrkB in inclusion bodies (Bowden et al, 
1991) which resulted to be around 20 KDa, as it was expected. 
After harvested cells were sonicated we could start clarifying the inclusion 
bodies containing the protein  following Palmer, I, Wingfield, PT 1995. 
Purified inclusion bodies were solubilised in a urea containing buffer as in 
our reference article protein was found in the urea-soluble fractions.  
A chromatographic Ni-nta column was used, under reducing conditions in 
order to obtain only the secondary structure, more favourable for the 
protein-bead interaction.    
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TrkBIg2 was then eluted trying different concentrations of imidazole in 
order to find the one that most suited the purification. 
 
Figure 3.5 The protein TrkBIg2 eluted from the column at different 
concentration of Imidazole. 
 
In the end we found out the best concentration was 300 mM Imidazole as 
shown in figure 3.5. 
The fractions containing the protein eluted from the Immobilized metal ion 
affinity chromatography, were concentrated and poured into a Superdex 
200 gel-filtration column. Nonreducing conditions were maintained in 
order to get the protein refolded as close as possible to its natural 3D 
structure (Jaenicke and Rudolph, 1990). 
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Figure 3.6 Checking the presence of the protein in the eluted fractions 
In the first row there are various concentrations of BSA and the staining 
solution, from the first well of the second row on there are all the fractions 
eluted from the gel filtration column. In well number 5 is visible a big 
amount of protein due to the presence of aggregates and the dimer and 
from well 31 on the second peak of TrkBIg2 monomer is detectable. 
 
We aimed to get the protein refolded in its natural conformation (figure 
3.7), thus able to interact with its natural ligand or - as TrkB had to be used 
the target for the phage display - a 12mer peptide. 
 
Figure 3.7 The model BDNF-TrkBIg2 complex (dark red–dark blue) 
Taken from Naylor’s article, 2002 
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Figure 3.8 Fractions eluted from the gel filtration column 
 
Figure 3.9 Fractions eluted from the gel filtration column 
In the first well fractions eluted from the Ni-nta gel before loading them on 
the superdex column, from well 2 on fractions collected progressively from 
the gel filtration column (superdex) 
 
Comparing TrkB purification progress with others performed with known 
molecular weight proteins like BSA and Lysozyme, we estimated that the 
protein had to be eluted approximately after a certain volume of buffer had 
flowed through. 
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The binding domain was found in the pool of eluted fraction but unluckily 
the presence of another protein weighting about 45kDa, probably naturally 
produced by the E.coli, was as well detected, as shown in figures 3.8, 3.9. 
We then performed a native protein electrophoresis in order to investigate 
on the presence of the contaminant or aggregate in the various fractions and 
to know if the protein could be somehow detached from its dimer. 
This technique does not use any denaturant agent thus leaving the proteins 
intact, in their native form, as they have to be used in the phage selection. 
This allowed separation of TrkBIg2 monomer from dimer and aggregate. 
And we could eventually see that fractions from the peak corresponding to 
a molecular weight of approximately 18.5 kDa contained TrkBIg2 
monomer.
 
Figure 3.10 In the native gel, the monomer is separated from the dimer 
We then pooled all the fractions and added the Ni-Nta gel in order to 
immobilize the His tagged binding domain to the beads. This represented 
the first step of the phage display. 
Our idea was letting the phages stick to the Nickel-bound protein, washing 
away the aspecific phages and subsequently cutting the protein from the 
beads taking advantage of the presence of a thrombin cleavage site between 
the His tag and the protein. 
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We found that a similar experiment had been performed on Nickel-beads-
attached protein with a different enzyme (Clackson T, Lowman H, 2004). 
This way we could perform the phage display technique in just one go. 
When using phage display in fact, it is always necessary to “subtract” from 
the selected phages the ones that did not actually bind the target but 
something else like, in this case, the beads could be. 
Cutting the protein with thrombin instead, the beads with the His tag 
(which is obviously not a part of the binding domain) and the phages 
attached would be left, while only the specific phages would be collected. 
The parameters to set the thrombin cleavage in beads were set. 
 
BDNF 
As during phage display a wash with a competitor is needed to have the 
phages detached from the target, we worked to get TrkB natural ligand, 
BDNF. 
The gene was scratched from the same cDNA library from adult human 
brain obtained while we were studying TrkB.  
In literature many isoforms of the neurotrophin could be found but as they 
have mainly the same coding sequence we chose the most frequent which 
is a DNA fragment 744 bp long (Lewin and Barde, 1996) 
The gene, amplified by specific primers, was inserted into a prokaryotic 
expression vector. After transforming the proper cells and inducing them 
we realized in an SDS page assay that the protein was not expressed by 
E.Coli. 
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This could be probably due to the fact that E.Coli and bacteria in general 
have a different codon usage from the eukaryotic organisms (Phillips et al , 
1987) 
So we “translated” all the nucleotide sequence of BDNF in something that 
could be more easily “read” by bacteria (figure 3.11). 
Moreover we found out that we could try to get just the mature form of the 
NT synthesized which was about 300bp shorter. 
Colors: = less than 10% of codons for same amino acid; = at least 10% 
Fraction of sense codons below threshold (=10.00): 0/140 (0%) 
Figure 3.11 E. coli Codon Usage Analysis for the new BDNF 
 
So we designed a completely new “easily translatable” BDNF and we 
finally obtained the DNA, performing many amplification cycles with 10 
overlapping primers. 
When the BDNF gene was successively inserted into a cloning vector and 
sequenced some mutations were found, due to proofreading mistakes by the 
polymerase and they were fixed with a site specific mutagenesis. 
After sequencing BDNF gene it was inserted into a pET28 expression 
vector and the protein expression in E.coli was achieved as shown in figure 
3.12. 
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Figure 3.12 E. coli BL21cells expressing BDNF, selecting the best clone 
and setting the time of induction  
 
TRK B FULL LENGTH 
 
We also took into consideration the possibility of performing a phage 
display in vitro on the real protein, expressed by eukaryotic cells, thus more 
reliable as a model. 
Trk receptors are heavily N-glycosylated in their extracellular portions. 
As Watson et al. in 1999 demonstrated, glycosylation serves two distinct 
functions: regulation of Trk surface expression and prevention of ligand-
independent Trk activity.  
Trk core protein is continuously active in vitro. 
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Consequently, factors that alter Trk receptor N-glycosylation can 
profoundly modulate the activation capacity of the receptor.  
This could represent a problem in production of TrkB in E.coli as the 
receptor will certainly not be N-glycosilated.  
N-glycosylation is instead a normal post-translational process in eukaryotic 
cells. 
This was the reason why eukaryotic cells were chosen to produce the best 
targets for the selection of peptides despite the much longer time the 
process requires. 
We prepared a plasmid containing TrkB full length gene inserted into an 
eukaryotic vector, pcDNA3.1 (the structure is shown in figure 3.13). 
The starting material for the transfection was a cell line derived from 
human cervical cancer cells (HeLa). 
About 40 hours after the transfection, we could prove that the receptor was 
actually expressed by the cells as the immunocytology assay confirmed. 
Cells’ fluorescence was in fact detectable following the immunoreaction, 
(figures 3.14), thus demonstrating first of all that the sequence coded for 
the protein and subsequently that Hela cells could be used for both transient 
and stable transfection. 
The presence of the BDNF receptor was also confirmed in cochleas’ 
sections from mouse, rat and guinea pig with an immunohistochemical 
assay (fig 3.15). 
TrkB was especially detected in cavia’s inner ear. This  fact made us take 
into  consideration that the phage display on guinea pig could be as well 
performed, giving comparable results to the one obtained on the human 
model. 
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Figure 3.13 TrkB full length in pcDNA3.1 
 
 
Figure 3.14 Immunocytofluorescence of Hela cells. a) negative control, b) 
transfected cells 
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Figure 3.15 TrkB detected in cochleas from rat (first lane), mouse (second 
lane) and guinea pig (third lane). 
 
A simpler and quicker method to detect the ectopic TrkB is having it fused 
with a fluorescent protein like GFP.  
Having the receptor traceable in transfected cells could help us in the 
creation of a stable cell line containing TrkB. 
Green fluorescent protein is one of the most useful reporter genes for 
marking transfected cells in vivo, it is expressed in the outer dermal layer of 
the Pacific Northwest jellyfish Aequorea victoria. 
GFP autofluorescence provides a green bioluminescent light to the jellyfish 
in response to a calcium-dependent energy transfer step involving a GFP-
associated protein called aequorin.  
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Exposure to ultraviolet light causes GFP to autofluoresce a bright green 
color within living cells, even in the absence of aequorin, calcium, or any 
other cofactor or substrate. 
 
PCDNA3.1-egfp-trkb
8572 bp
EGFP
trkb flneomycin
PUTATIVE TRANSCRIPTIONAL START
TATA
F1 origin
amp resist
orf 2 XbaI (4136)
BamHI (930)
BamHI (1656)
HindIII (912)
HindIII (1927)
NdeI (485)
NdeI (2380)
BglII (13)
BglII (2452)
BglII (3361)
 
Figure 3.16 pcDNA3.1 construct with TrkB and the gene coding for the 
green fluorescent protein GFP. 
We excised GFP sequence from the backbone of an EGFP vector and 
inserted that in the pcDNA3.1-TrkB vector we already had. 
We successfully transfected cells as shown in figure 3.16. 
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Figure 3.17 Hela cells transfected with GFP-TrkB full length  
 
As the huge therapeutic potential of neurotrophins is known many attempts 
were made to obtain smaller and handier peptides, not all of them were 
successful and many times the mimetic molecules resulted in being 
antagonists instead (O’Leary and Hughes, 2003; Zhongcai et al, 2003). 
A good way to narrow the different options is comparing peptides 
sequences obtained from different sources. 
Considering the great homology of neurotrophic factors within species  
(Shelton et al, 1995) we took into consideration the possibility of 
performing the peptide selection in vivo, too as it had been done already 
(Rajotte et al 1998 Sergeeva et al, 2006). 
We infact performed the same technique on guinea pigs cochleas.  
 89 
After cochleostomy and incubation of the phages, caviae were sacrificed 
and cochleas collected. 
Harvested phages were used to infect bacteria, and the pool of peptides 
could still be enriched as three rounds were performed. 
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4. CONCLUSIONS 
Communication disability in profoundly deaf individuals can be alleviated 
by cochlear implants, which are electromagnetic devices that directly 
stimulate the sensory neurons. 
In most cases in fact, auditory impairment results from the death of sensory 
hair cells in the Organ of Corti, while the auditory nerve remains 
functional. 
This fact has great significance as cochlear implants work only if suitable 
numbers of sensory neurons are preserved.  
The auditory sensory neurons usually undergo a slow, nearly complete 
degeneration in the absence of hair cells and this degenerative process 
accelerates when the entire Organ of Corti degenerates.  
Prevention of death of auditory sensory neurons is thus of great therapeutic 
importance, even if hair cells cannot be rescued or regenerated. 
A target delivery of therapeutic agents to the neurons of the spiral ganglion 
in the cochlea could be a huge enhancement in this sense. 
The Brain Derived Neurotrophic Factor has been taken into consideration 
to direct nanoparticles with a payload of drugs towards TrkB receptors 
expressed in neurons’ membrane. 
Smaller peptides mimicking its effect have to be used as BDNF can’t be 
administered.  
One of the aims of the Nanoear European project we are involved in is 
attaching these peptides to nanoparticles that could then be injected into the 
inner ear. 
In collaboration with Yorkshire Bioscience Ltd I worked to set all the 
parameters to perform the phage display technique. 
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This technique allows the selection of specific peptides using the natural 
receptor as a target. 
My task was then to provide the target and the best conditions for the 
experiment to be carried on. 
A study in literature was taken on to find the most representative target 
which is an isoform of BDNF receptor expressed in particular in the inner 
ear. 
The gene coding for this receptor, TrkB, was obtained and transfected in 
mammalian cells in order to get the protein with its natural structure and all 
the post-translational modifications. 
The more specific binding domain of the protein was also expressed in 
large quantities in bacteria and a protocol to purify it was optimized. 
Based on the great homology among species, an in vivo phage display was 
also performed using guinea pigs’ cochleas, which is still in progress. 
This study lays the foundations for the screening of peptides mimicking 
BDNF and hopefully ameliorating cochear implant design and 
performances. 
Even if the road to walk is still long, the results obtained here are the first 
promising steps in the process of finding what it is very likely to become a 
new kind of drug. 
The peptides that are about to be screened, included in nanoparticles easier 
to administer in the inner ear  in fact have a great potential either for the 
target delivery and, as drugs themselves, for the protection and the 
maintenance of the auditory system in cochlear prosthesis users. 
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